

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

Jackson Laboratory Clinical Knowledgebase

RRID:SCR_014965

Type: Tool

Proper Citation

Jackson Laboratory Clinical Knowledgebase (RRID:SCR_014965)

Resource Information

URL: <https://ckb.jax.org/>

Proper Citation: Jackson Laboratory Clinical Knowledgebase (RRID:SCR_014965)

Description: Semi-automated and manually curated database of gene/variant annotations, therapy knowledge, diagnostic/prognostic information, and oncology clinical trials. Users can search CKB via gene, gene variants, drug, drug class, indication, and clinical trials.

Abbreviations: CKB

Synonyms: Jackson CKB

Resource Type: data or information resource, database

Defining Citation: [PMID:26772741](#)

Keywords: cancer, database, knowledgebase, clinical trial, clinical, gene, gene annotation, variant annotation, therapy, diagnosis

Related Condition: Cancer

Availability: Available to the research community, For educational and research purposes only, Not intended to be used for medical advice/diagnosis or treatment

Resource Name: Jackson Laboratory Clinical Knowledgebase

Resource ID: SCR_014965

Record Creation Time: 20220129T080323+0000

Record Last Update: 20260729T044336+0000

Ratings and Alerts

No rating or validation information has been found for Jackson Laboratory Clinical Knowledgebase.

No alerts have been found for Jackson Laboratory Clinical Knowledgebase.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Yoshimura T, et al. (2025) Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification. BJC reports, 3(1), 37.

Chikaishi Y, et al. (2025) Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications. Cancer science, 116(4), 1082.

Suzuki S, et al. (2025) Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration. PloS one, 20(1), e0305025.

Arai M, et al. (2025) Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma. Cancer immunology, immunotherapy : CII, 74(5), 166.

Steenbock O, et al. (2025) [Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate]. Urologie (Heidelberg, Germany), 64(3), 256.

Saito A, et al. (2024) Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data. Cancer medicine, 13(4), e7077.

Eerkens AL, et al. (2024) Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study. Nature communications, 15(1), 7695.

Chida A, et al. (2024) Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia. Oncology letters, 28(6), 568.

Takano N, et al. (2024) Genetic and histological analysis intraplacental choriocarcinoma: a case report. Medical molecular morphology, 57(2), 147.

Gazola AA, et al. (2024) Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment. Molecular cytogenetics, 17(1), 28.

- Kumbrink J, et al. (2024) Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting. *Pathology oncology research : POR*, 30, 1611590.
- Stahler A, et al. (2024) Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1256.
- Sakamoto T, et al. (2023) Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. *BMC cancer*, 23(1), 71.
- Higa N, et al. (2023) Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma. *Cancer medicine*, 12(1), 49.
- Takamatsu R, et al. (2023) Clinical predominance of whole-exome sequencing to evaluate microsatellite instability status. *Cancer science*, 114(7), 2848.
- Serebriiskii IG, et al. (2022) Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. *Nature communications*, 13(1), 1618.
- Bu R, et al. (2021) Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer. *Frontiers in oncology*, 11, 670423.
- Niu L, et al. (2021) Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer. *Oncology letters*, 22(2), 594.
- Shimozaki K, et al. (2021) Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. *Scientific reports*, 11(1), 20003.
- Moniz CMV, et al. (2021) A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. *Journal of Cancer*, 12(23), 7018.